APA
van d. H. D., Braun J., Rudwaleit M., Purcaru O. & Kavanaugh A. (20160610). Sustained Improvements in Workplace and Household Productivity and Social Participation With Certolizumab Pegol Over 96 Weeks in Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis. : Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
Chicago
van der Heijde D, Braun J, Rudwaleit M, Purcaru O and Kavanaugh A. 20160610. Sustained Improvements in Workplace and Household Productivity and Social Participation With Certolizumab Pegol Over 96 Weeks in Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis. : Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
Harvard
van d. H. D., Braun J., Rudwaleit M., Purcaru O. and Kavanaugh A. (20160610). Sustained Improvements in Workplace and Household Productivity and Social Participation With Certolizumab Pegol Over 96 Weeks in Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis. : Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
MLA
van der Heijde D, Braun J, Rudwaleit M, Purcaru O and Kavanaugh A. Sustained Improvements in Workplace and Household Productivity and Social Participation With Certolizumab Pegol Over 96 Weeks in Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis. : Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 20160610.